ZNF23

Summary

ZNF23 (zinc finger protein 23, HGNC:13023) is a protein-coding gene on chromosome 16q22.2, encoding Zinc finger protein 23 (P17027). May be involved in transcriptional regulation.

Enables sequence-specific double-stranded DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 7571 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 104 total
• MANE Select transcript: NM_001381984

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13023
Approved symbol	ZNF23
Name	zinc finger protein 23
Location	16q22.2
Locus type	gene with protein product
Status	Approved
Aliases	KOX16, Zfp612, ZNF612
Ensembl gene	ENSG00000167377
Ensembl biotype	protein_coding
OMIM	194527
Entrez	7571

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000357254, ENST00000358700, ENST00000393539, ENST00000497160, ENST00000539742, ENST00000564528, ENST00000564588, ENST00000565718, ENST00000567340, ENST00000576258, ENST00000647773, ENST00000879622, ENST00000913285, ENST00000949091, ENST00000949092

RefSeq mRNA: 22 — MANE Select: NM_001381984 NM_001304492, NM_001304493, NM_001304494, NM_001381965, NM_001381966, NM_001381967, NM_001381968, NM_001381969, NM_001381970, NM_001381971, NM_001381972, NM_001381973, NM_001381974, NM_001381975, NM_001381976, NM_001381977, NM_001381978, NM_001381979, NM_001381980, NM_001381981, NM_001381984, NM_145911

CCDS: CCDS10900, CCDS76895, CCDS92194

Canonical transcript exons

ENST00000647773 — 5 exons

Exon	Start	End
ENSE00002603890	71456764	71456828
ENSE00003765796	71453243	71453350
ENSE00003832527	71454042	71454168
ENSE00003839164	71447597	71449885
ENSE00003938437	71462210	71462247

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 90.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.7261 / max 54.9518, expressed in 1553 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158005	3.7261	1553

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	90.71	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.45	gold quality
pituitary gland	UBERON:0000007	86.51	gold quality
adenohypophysis	UBERON:0002196	86.33	gold quality
right uterine tube	UBERON:0001302	85.86	gold quality
ganglionic eminence	UBERON:0004023	85.69	gold quality
cerebellar hemisphere	UBERON:0002245	85.45	gold quality
cerebellar cortex	UBERON:0002129	85.42	gold quality
sural nerve	UBERON:0015488	85.37	gold quality
cerebellum	UBERON:0002037	85.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.64	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.53	gold quality
hypothalamus	UBERON:0001898	84.11	gold quality
Ammon’s horn	UBERON:0001954	83.86	gold quality
amygdala	UBERON:0001876	83.65	gold quality
brain	UBERON:0000955	83.60	gold quality
temporal lobe	UBERON:0001871	83.57	gold quality
nucleus accumbens	UBERON:0001882	83.33	gold quality
caudate nucleus	UBERON:0001873	83.04	gold quality
cerebral cortex	UBERON:0000956	83.02	gold quality
primary visual cortex	UBERON:0002436	83.01	gold quality
right frontal lobe	UBERON:0002810	82.97	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.96	gold quality
anterior cingulate cortex	UBERON:0009835	82.87	gold quality
superior frontal gyrus	UBERON:0002661	82.84	gold quality
putamen	UBERON:0001874	82.81	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	82.74	gold quality
frontal cortex	UBERON:0001870	82.73	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.71	gold quality
stromal cell of endometrium	CL:0002255	82.69	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ENAD-17	no	571.60
E-ANND-3	no	3.42

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

37 targeting ZNF23, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-4502	99.65	66.99	1021
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-136-5P	99.50	67.26	1153
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-150-3P	99.43	70.51	920
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-4528	99.18	69.77	1936
HSA-MIR-4451	98.82	68.17	1455
HSA-MIR-6755-3P	98.61	66.90	834
HSA-MIR-640	98.44	66.93	644

Literature-anchored findings (GeneRIF, showing 7)

• Characterization of ZNF359 and its role in human development (PMID:12127974)
• ZNF23 is a new member of KRAB-ZNF superfamily with growth-inhibitory ability and its downregulation may contribute to carcinogenesis (PMID:17137575)
• ZNF23 induced apoptosis partially via down-regulation of Bcl-XL. (PMID:18384939)
• ZNF23 gene could play an important role in the development of hepatocellular carcinoma. (PMID:21965783)
• Ectopic expression of ZNF23 induced cell apoptosis by activation of caspase-3, p27, p53 expression and down-regulation of Bcl-2 through mitochondria-dependent pathway. (PMID:28848158)
• Nucleolar small molecule RNA SNORA75 promotes endometrial receptivity by regulating the function of miR-146a-3p and ZNF23. (PMID:34030136)
• Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription. (PMID:34923485)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp612	ENSMUSG00000044676
rattus_norvegicus	Zfp612	ENSRNOG00000016971

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 23 — P17027 (reviewed: P17027)

Alternative names: Zinc finger protein 359, Zinc finger protein 612, Zinc finger protein KOX16

All UniProt accessions (6): A0A3B3ITE4, P17027, H0Y310, H3BMC6, H3BPE6, H3BSF8

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation. May have a role in embryonic development.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
P17027-1	1	yes
P17027-2	2

RefSeq proteins (22): NP_001291421, NP_001291422, NP_001291423, NP_001368894, NP_001368895, NP_001368896, NP_001368897, NP_001368898, NP_001368899, NP_001368900, NP_001368901, NP_001368902, NP_001368903, NP_001368904, NP_001368905, NP_001368906, NP_001368907, NP_001368908, NP_001368909, NP_001368910, NP_001368913, NP_666016 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050826	Krueppel_C2H2_ZnFinger	Family

Pfam: PF00096

UniProt features (23 total): zinc finger region 17, chain 1, domain 1, cross-link 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P17027-F1	72.27	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 157

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 109 (showing top): YAGI_AML_WITH_INV_16_TRANSLOCATION, chr16q22, BACH2_01, P300_01, NRF2_01, HAN_SATB1_TARGETS_DN, NERF_Q2, AP1FJ_Q2, CHEN_HOXA5_TARGETS_9HR_UP, SCGGAAGY_ELK1_02, MGGAAGTG_GABP_B, MATSUDA_NATURAL_KILLER_DIFFERENTIATION, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, ELK1_02, WONG_ADULT_TISSUE_STEM_MODULE

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

448 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF23	NOX4	Q9NPH5	777
ZNF23	ACBD6	Q9BR61	673
ZNF23	ASCL3	Q9NQ33	475
ZNF23	RASGEF1C	Q8N431	424
ZNF23	COMTD1	Q86VU5	409
ZNF23	ANKRD7	Q92527	367
ZNF23	PHYHIPL	Q96FC7	362
ZNF23	ZSWIM3	Q96MP5	350
ZNF23	CEACAM20	Q6UY09	349
ZNF23	TMBIM4	Q9HC24	348
ZNF23	COMMD5	Q9GZQ3	341
ZNF23	CARMIL3	Q8ND23	339
ZNF23	RPS7	P23821	335
ZNF23	CIRSR	Q86X95	333
ZNF23	FRA10AC1	Q70Z53	323

IntAct

65 interactions, top by confidence:

A	B	Type	Score
SPRY1	ZNF23	psi-mi:“MI:0915”(physical association)	0.600
ZNF23	SPRY1	psi-mi:“MI:0915”(physical association)	0.600
	ZNF23	psi-mi:“MI:0915”(physical association)	0.560
ZNF23		psi-mi:“MI:0915”(physical association)	0.560
ZNF23	MCRS1	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	GMCL1	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	TRAF1	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	MOBP	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	FHL2	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	MDFI	psi-mi:“MI:0915”(physical association)	0.560
ZNF330	ZNF23	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	FHL5	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	TSGA10	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	ELOA2	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	NME7	psi-mi:“MI:0915”(physical association)	0.560
ZNF23	ZNF330	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (28): KRTAP10-3 (Two-hybrid), ZNF23 (Affinity Capture-RNA), ZNF23 (Two-hybrid), GTF2IRD1 (Affinity Capture-MS), TWISTNB (Affinity Capture-MS), HDGFRP3 (Affinity Capture-MS), ARID2 (Affinity Capture-MS), ZNF23 (Two-hybrid), ZNF23 (Two-hybrid), ZNF23 (Two-hybrid), ZNF23 (Two-hybrid), ZNF23 (Two-hybrid), ZNF23 (Two-hybrid), ZNF23 (Two-hybrid), ZNF23 (Two-hybrid)

ESM2 similar proteins: A2VDQ7, A6NNF4, A8MQ14, A8MTY0, E9QAG8, O75290, O75373, P08043, P0CJ79, P10751, P17017, P17027, P17039, P35789, P51522, P51523, Q08AN1, Q14585, Q14587, Q3SYV7, Q3ZCX4, Q4R4C7, Q52M93, Q5MCW4, Q5R5U3, Q5R8X1, Q5R9F0, Q5SXM1, Q6ECI4, Q6JLC9, Q6P3V2, Q6P5C7, Q6ZN57, Q86UE3, Q86XN6, Q86YE8, Q8C827, Q8IYB9, Q8N4W9, Q8N7M2

Diamond homologs: P17023, P17027, Q5R7I8, Q9BRH9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	73
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1576 predictions. Top by Δscore:

Variant	Effect	Δscore
16:71449881:ATCTA:A	acceptor_gain	1.0000
16:71449883:CTA:C	acceptor_gain	1.0000
16:71449884:TA:T	acceptor_gain	1.0000
16:71449886:C:CC	acceptor_gain	1.0000
16:71449888:A:C	acceptor_gain	1.0000
16:71455961:T:C	donor_gain	1.0000
16:71449882:TCTA:T	acceptor_loss	0.9900
16:71449882:TCTAC:T	acceptor_gain	0.9900
16:71449883:CTACT:C	acceptor_gain	0.9900
16:71449884:TACTA:T	acceptor_loss	0.9900
16:71449885:AC:A	acceptor_loss	0.9900
16:71449886:C:G	acceptor_loss	0.9900
16:71449886:C:T	acceptor_loss	0.9900
16:71449887:T:A	acceptor_loss	0.9900
16:71449887:T:G	acceptor_loss	0.9900
16:71449888:A:AC	acceptor_gain	0.9900
16:71453236:C:A	donor_gain	0.9900
16:71453242:CCAGT:C	donor_gain	0.9900
16:71454332:C:CT	donor_gain	0.9900
16:71454333:T:TT	donor_gain	0.9900
16:71455913:C:A	donor_gain	0.9900
16:71455960:A:AC	donor_gain	0.9900
16:71455960:AT:A	donor_gain	0.9900
16:71456825:GGAGC:G	acceptor_gain	0.9900
16:71456829:C:CC	acceptor_gain	0.9900
16:71462368:CCC:C	acceptor_gain	0.9900
16:71462369:CCC:C	acceptor_gain	0.9900
16:71454035:GTCTT:G	donor_loss	0.9800
16:71454036:TCTTA:T	donor_loss	0.9800
16:71454037:CTTAC:C	donor_loss	0.9800

AlphaMissense

4630 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:71448486:G:C	F513L	0.999
16:71448486:G:T	F513L	0.999
16:71448488:A:G	F513L	0.999
16:71449074:G:C	F317L	0.999
16:71449074:G:T	F317L	0.999
16:71449076:A:G	F317L	0.999
16:71448318:G:C	F569L	0.998
16:71448318:G:T	F569L	0.998
16:71448320:A:G	F569L	0.998
16:71448538:C:G	R496P	0.998
16:71448654:G:C	F457L	0.998
16:71448654:G:T	F457L	0.998
16:71448656:A:G	F457L	0.998
16:71448822:G:C	F401L	0.998
16:71448822:G:T	F401L	0.998
16:71448824:A:G	F401L	0.998
16:71448990:G:C	F345L	0.998
16:71448990:G:T	F345L	0.998
16:71448992:A:G	F345L	0.998
16:71449158:G:C	F289L	0.998
16:71449158:G:T	F289L	0.998
16:71449160:A:G	F289L	0.998
16:71448402:G:C	F541L	0.997
16:71448402:G:T	F541L	0.997
16:71448404:A:G	F541L	0.997
16:71448566:A:G	S487P	0.997
16:71448570:A:C	F485L	0.997
16:71448570:A:T	F485L	0.997
16:71448572:A:G	F485L	0.997
16:71448738:G:C	F429L	0.997

dbSNP variants (sampled 300 via entrez): RS1000379998 (16:71458483 G>A,C), RS1000411217 (16:71458726 G>A), RS1000490315 (16:71451892 A>G), RS1000591883 (16:71452180 G>A,C,T), RS1000869773 (16:71447293 A>G,T), RS1001026306 (16:71447586 G>A), RS1001173405 (16:71461690 T>C), RS1001928248 (16:71451041 G>T), RS1002210206 (16:71463011 A>G), RS1002210813 (16:71453948 G>C), RS1002245636 (16:71447977 C>G,T), RS1002562777 (16:71447715 A>G), RS1002632970 (16:71462737 C>G), RS1002881515 (16:71460575 C>T), RS1003180798 (16:71454596 C>A,G,T)

Disease associations

OMIM: gene MIM:194527 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007325_161	General risk tolerance (MTAG)	2.000000e-11
GCST008161_1	Waist circumference adjusted for body mass index	5.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008579	risk-taking behaviour
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
geraniol	increases expression	1
terbufos	decreases methylation	1
methacrylaldehyde	increases expression, increases abundance, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression, decreases reaction	1
Bortezomib	increases expression	1
Temozolomide	decreases expression	1
Acrolein	affects cotreatment, increases expression, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases expression	1
Vehicle Emissions	decreases reaction, increases expression	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Fonofos	decreases methylation	1
Gallic Acid	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Ozone	affects cotreatment, increases expression, increases abundance	1
Parathion	decreases methylation	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Aflatoxin B1	decreases expression	1
Gold Compounds	decreases expression	1
Cadmium Chloride	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW23	HEK293 eGFP-ZNF23	Transformed cell line	Female

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome